Screening of microRNAs for a repressor of hepatitis B virus replication

Yutaka Naito; Susumu Hamada-Tsutsumi; Yusuke Yamamoto; Akiko Kogure; Yusuke Yoshioka; Koichi Watashi; Takahiro Ochiya; Yasuhito Tanaka

doi:10.18632/oncotarget.25557

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Screening of microRNAs for a repressor of hepatitis B virus replication

Yutaka Naito, Susumu Hamada-Tsutsumi, Yusuke Yamamoto, Akiko Kogure, Yusuke Yoshioka, Koichi Watashi, Takahiro Ochiya and Yasuhito Tanaka _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:29857-29868. https://doi.org/10.18632/oncotarget.25557

Metrics: PDF 1429 views | HTML 1882 views | ?

Abstract

Yutaka Naito1,*, Susumu Hamada-Tsutsumi2,*, Yusuke Yamamoto1, Akiko Kogure1, Yusuke Yoshioka1, Koichi Watashi3, Takahiro Ochiya1 and Yasuhito Tanaka2

1Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tokyo, Japan

2Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

3Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan

*These authors have contributed equally to this work

Correspondence to:

Yasuhito Tanaka, email: [email protected]

Keywords: hepatitis B virus; microRNA; miR-204; Rab22a

Received: October 27, 2017 Accepted: May 13, 2018 Published: July 06, 2018

ABSTRACT

Background: Hepatitis B virus (HBV) infection is a leading cause of persistent liver diseases, cirrhosis and hepatocellular carcinoma (HCC) worldwide. Since deregulation of microRNA (miRNA) expression by HBV infection contributes to enhanced viral replication and pathogenesis, modulation of miRNA activity can be a novel therapeutic approach towards HBV eradication. As the effects of the vast majority of miRNAs on HBV replication have not been empirically investigated, here, we aim to identify novel therapeutic targets that have a strong antiviral effect on HBV.

Methods: HepG2-hNTCP-C4 cells were infected with HBV, and then were individually transfected with the library mimics of 2048 miRNAs. To assess the amount of intracellular and extracellular DNA and HBsAg, qPCR and ELISA were performed respectively.

Results: From miRNA library screening, we identified 39 miRNAs as candidate repressors of HBV replication. Among them, 9 miRNAs, including miR-204, strongly decreased both HBV DNA and HBsAg in culture supernatant of HepG2-hNTCP-C4 cells. Furthermore, we also showed that inhibition of Rab22a, one of the targets of miR-204, also suppressed intracellular and extracellular HBV DNA expression in HepG2.2.15.7 cells.

Conclusions: Our findings contribute to the understanding of the roles of miRNAs underlying HBV replication and show the possibility of developing a novel strategy for miRNA-mediated HBV treatment.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25557

Publication Alerts

Research Papers:

Screening of microRNAs for a repressor of hepatitis B virus replication

Abstract